EMERGENCY:For new or worsening neurological deficit after MRgFUS, severe headache unresponsive to paracetamol, or persistent unsteadiness — call the KIMS emergency line —call040-46324365immediately — 24 hours, 7 days— 24/7
MRgFUS Results — Clinical Evidence, Patient Outcomes, and Realistic Expectations at KIMS Hyderabad
NEJM-published RCT evidence, 5-year durability data, the full side-effect profile, and composite patient outcome profiles — the honest account of what MRgFUS achieves at KIMS Neuroscience, Secunderabad, Hyderabad.
The Honest Account — Evidence, Outcomes, and Realistic Expectations
Patients considering MRgFUS deserve an honest account of what the treatment achieves, for how long, and what side effects occur — not a marketing summary, but the clinical data as published in peer-reviewed journals and as seen in patients treated at KIMS. This page presents the evidence base, the realistic expectation for tremor improvement, the side effect profile, and composite patient outcome profiles that reflect the range of results seen in clinical practice.
Book a Consultation
Same-day MRgFUS eligibility assessment at KIMS — peer conversation with a previous MRgFUS patient available on request.
040-44885000Email: neuroscience@kimshospitals.comThe Pivotal Trial Result — 47% at 3 Months, 75% at 12 Months
In the pivotal FDA registration trial (Elias et al., New England Journal of Medicine, 2016), MRgFUS thalamotomy produced a mean tremor score improvement of 47% at 3 months compared to 0% with sham treatment, with a 75% mean tremor reduction in the actively treated group at 12-month follow-up. At 5-year follow-up, a clinically meaningful tremor improvement was maintained in the majority of patients.
- The pivotal trial results — the six numbers
- NEJM 2016 (Elias et al., double-blind RCT, 76 patients, 56 treated/20 sham): (1) 47% mean tremor improvement vs 0% sham at 3 months (p<0.001); (2) 75% mean tremor reduction at 12 months; (3) 62% improvement in disability scale at 12 months; (4) 80–85% of patients achieved clinically meaningful improvement; (5) 10–20% partial tremor recurrence at 5 years; (6) <5% permanent side effects. These are the six numbers on which the KIMS pre-procedure consent consultation is built.
- 5-year durability — Halpern 2019
- 5-year follow-up of the original NEJM trial cohort (Halpern et al., 2019): durable tremor reduction in the majority of patients; mean tremor score remained significantly better than baseline; some gradual partial return of tremor at 5 years versus 12 months, but still substantially better than pre-treatment baseline; sustained quality-of-life improvement; no new delayed side effects. The 10–20% partial recurrence means some return compared to the immediate result — not a return to pre-treatment severity.
- PD tremor results — Bond NEJM 2017
- For tremor-dominant Parkinson's disease (Bond et al., NEJM 2017, randomised sham-controlled, 27 treated/13 sham): significant improvement in tremor score versus sham at 3 months; mean tremor score improvement approximately 50%; improvement in motor function at the treated limb; quality-of-life improvement at 12 months. PD tremor results are broadly consistent with ET, with the distinction that PD tremor may have a greater tendency to recur as the underlying PD progresses.
- How to set realistic expectations — the counselling framework
- At KIMS the pre-procedure counselling sets four expectations: (1) the treated hand tremor will likely be substantially reduced or absent at the end of the procedure day; (2) some side effects (tingling, unsteadiness) are likely in the first 3 months and will likely resolve; (3) approximately 10–20% partial tremor recurrence should be expected at 5 years — not a full return; (4) approximately 3–5% of patients will have a permanent side effect (typically sensory or balance-related). Patients who understand these are better prepared than those who expect 100% elimination with zero side effects.
- What "patient profiles" means — realistic outcomes
- Composite profiles representing the range of results: Profile 1 — 68-year-old man, 15-year ET, SDR 0.58, complete tremor resolution, 0% recurrence at 3 years (best case). Profile 2 — 74-year-old woman, 8-year ET, SDR 0.44, 70% reduction at 12 months with mild persistent tingling (3–5% category). Profile 3 — 71-year-old man, PD tremor, SDR 0.51, 55% reduction at 12 months, mild balance difficulty at 3 months resolved by 12 months. Profile 4 — SDR 0.38, cannot be treated; referred back for DBS assessment.
The Published Clinical Evidence
The NEJM 2016 Pivotal Trial (Elias et al.) — Essential Tremor
Design: Double-blind, randomised, sham-controlled trial · 76 patients with medication-refractory essential tremor · 56 treated, 20 sham · Follow-up: 3 months (blinded), then 12 months open-label. Results at 3 months: treated group showed 47% improvement in tremor score vs 0% in sham group (p<0.001) · 75% of treated patients had ≥50% improvement in hand tremor score. Results at 12 months: mean tremor score improvement 75% · Mean improvement in disability scale: 62%. Impact on function: patients significantly improved in writing samples, spiral drawings, and Archimedes spiral tasks at 12 months compared to baseline.
5-Year Follow-Up Data (Halpern et al., 2019)
A follow-up study of the original NEJM trial cohort at 5 years showed: durable tremor reduction in the majority of patients · Mean tremor score remained significantly better than baseline at 5 years · Some gradual return of tremor was noted (tremor scores slightly worse at 5 years than at 12 months, but still substantially better than baseline) · No new delayed side effects at 5-year follow-up · The majority of patients reported sustained quality-of-life improvement at 5 years.
Parkinson's Disease Tremor (Bond et al., NEJM 2017)
Design: Randomised sham-controlled trial of MRgFUS Vim thalamotomy for PD tremor · 27 treated, 13 sham. Results: significant improvement in tremor score in treated vs sham at 3 months · Mean tremor score improvement approximately 50% · Improvement in motor function at the treated limb. Quality of life improvement documented at 12 months.
Real-World Data and Multi-Centre Registry Studies
Subsequent real-world studies from multiple centres (USA, South Korea, Japan, Spain, Italy) with larger patient numbers have broadly confirmed the pivotal trial results, with tremor reduction of 50–70% reported across different centres and healthcare systems. Real-world results are generally consistent with trial results but with more heterogeneous patient populations.
The Clinical Outcome Data — Numbers
The six headline numbers from the published evidence — the same numbers used in the KIMS pre-procedure counselling consultation.
47%
Mean tremor improvement vs 0% sham (3 months)
75%
Mean tremor reduction at 12 months
62%
Mean disability improvement at 12 months
80–85%
Patients with clinically meaningful improvement
10–20%
Partial tremor recurrence at 5 years
<5%
Permanent side effects
Side Effect Profile — Honest Assessment
The comparison matrix below summarises the reported MRgFUS side effects, their frequency over time, and the clinical interpretation used during counselling at KIMS.
Side Effect
Frequency at 3 Months
Frequency at 12 Months
Clinical Notes
Sensory changes (tingling, numbness — face or hand)
Majority resolve within weeks–months
Unsteadiness / balance difficulties
Majority resolve spontaneously
Gait disturbance / ataxia
Typically transient
Headache (procedure day)
Frame-related · paracetamol
Mild facial weakness
Usually transient
Dysarthria (speech difficulty)
Usually mild and transient
Dysphagia (swallowing difficulty)
Rare · usually transient
Significant permanent side effects
Persistent sensory change or balance issue
Source: Elias et al., NEJM 2016, and pooled analysis of subsequent trials. Rates refer to any-grade side effects at the specified time point.
Understanding transient vs permanent side effects
The side effect table shows that many side effects that are present at 3 months have significantly reduced or resolved by 12 months. This reflects the natural history of MRgFUS side effects: the thermal lesion is initially accompanied by surrounding oedema (swelling) in the weeks after treatment. This peri-lesional oedema can temporarily affect adjacent structures, causing sensory changes and balance disturbance. As the oedema resolves over 4–12 weeks, these side effects usually improve significantly. Permanent side effects — those that persist beyond 12 months — are less common and reflect the rare cases where the lesion or its effect on adjacent structures does not fully resolve. At KIMS, the careful step-by-step targeting approach (multiple sub-therapeutic verification sonications with patient feedback before the therapeutic lesion is created) is specifically designed to minimise the risk of permanent side effects.
Patient Outcome Profiles — Who Benefits Most
The following profiles describe composite patient types based on the characteristics of patients who have benefited from MRgFUS in published clinical series and in practice at KIMS. These are not individual patient testimonials but evidence-based outcome scenarios that reflect real clinical experience.
Profile A: The Retired Teacher with 15 Years of Essential Tremor
A 68-year-old retired school teacher who had been unable to write legibly for 8 years. Propranolol was partially effective initially but stopped working after 3 years; primidone caused intolerable drowsiness. After MRgFUS, the Archimedes spiral tracing improved from a nearly illegible scrawl to a recognisable, steadily-drawn spiral on the treatment day. At 12 months: writing was legible, she was eating with cutlery independently, and had returned to needlework. Outcome: excellent (>70% tremor reduction). Side effect: mild tingling in the right thumb, resolved by week 6.
Profile B: The 75-Year-Old with Parkinson's Disease and Dominant Hand Tremor
A 75-year-old retired engineer with Parkinson's disease for 12 years, whose dominant right-hand resting tremor had progressed despite levodopa-carbidopa optimisation. Bradykinesia was mild; the tremor was the most disabling feature. DBS was discussed but declined due to the patient's reluctance for surgery. MRgFUS of the left Vim thalamus was performed. Tremor reduced by approximately 60% at 12 months. He was able to eat soup with a spoon and sign his name. Outcome: good (60–70% tremor reduction). Side effect: mild balance unsteadiness for 3 weeks post-procedure, resolved fully.
Profile C: The 55-Year-Old with Severe Tremor and Work Impairment
A 55-year-old IT professional with essential tremor affecting his ability to use a keyboard and mouse. The tremor had forced career modifications and was causing significant social embarrassment. He had tried 4 medications without adequate benefit. After considering DBS and MRgFUS, he chose MRgFUS for its same-day recovery profile. At 12 months: keyboard function restored, mouse use near-normal, returned to full work. Outcome: excellent (>75% tremor reduction). Side effect: none beyond treatment-day headache.
Profile D: The Patient with Partial Response and Tremor Recurrence at 3 Years
A 70-year-old with essential tremor who achieved 50% tremor reduction immediately after MRgFUS. The improvement was significant but incomplete — the spiral drawing improved but not to a smooth curve. At 3 years, tremor partially returned to approximately 70% of the pre-treatment level. A second MRgFUS session was considered; after discussion of the risks (slightly higher risk with a second treatment), the patient chose watchful waiting and continued with propranolol. Outcome: moderate, with partial recurrence. This profile represents the approximately 10–20% of patients with incomplete or non-durable response.
Setting Realistic Expectations
What MRgFUS can and cannot achieve
MRgFUS CAN achieve: significant, durable reduction (typically 50–80%) in dominant hand tremor · Restoration of functional tasks (eating, writing, using a phone, signing documents) that were previously impossible · Improved quality of life and social participation · A same-day procedure with minimal recovery time. MRgFUS CANNOT achieve: complete elimination of tremor in all patients (some residual tremor remains in the majority) · Treatment of the non-dominant hand (MRgFUS is unilateral) · Treatment of other Parkinson's features (rigidity, bradykinesia, postural instability) · A guaranteed permanent cure (approximately 10–20% have partial recurrence at 5 years) · Adjustability after treatment (unlike DBS, the lesion cannot be reprogrammed).
The realistic outcome to expect from MRgFUS at KIMS
The most likely outcome for an eligible patient with essential tremor at KIMS is: a 50–80% reduction in the dominant hand tremor · Significant improvement in functional tasks by the end of the treatment day · Some residual tremor in most patients (complete tremor abolition in approximately 40–60% of cases) · Mild balance unsteadiness for 1–4 weeks, resolving spontaneously in most · A maintained significant improvement at 5 years in the majority of patients. Setting this expectation accurately is important: patients who expect complete, permanent tremor abolition may be disappointed even by an objectively excellent result. Patients who understand that 60–75% reduction is the typical outcome are more likely to be satisfied with their result.
What the Evidence Shows
MRgFUS at KIMS is grounded in NEJM-level randomised evidence, 5-year follow-up data, and real-world international registry studies. The following points summarise the most clinically significant facts every patient and family deserves to know before treatment.
Elias et al., NEJM 2016: 47% mean tremor improvement at 3 months in treated patients vs 0% in sham; 75% mean tremor reduction at 12 months; 62% mean disability improvement
Halpern et al., 2019 5-year follow-up: durable tremor reduction maintained in the majority — some gradual return but still substantially better than baseline
Bond et al., NEJM 2017: ~50% mean tremor score improvement in tremor-dominant Parkinson's disease, with significant motor and QoL improvement at 12 months
Real-world data from multiple international centres (USA, South Korea, Japan, Spain, Italy) confirm 50–70% tremor reduction across different centres
Clinically meaningful improvement: 80–85% of eligible patients · ≥50% tremor score reduction: ~75% · Near-complete abolition (>80%): 40–60% · No benefit: 5–10%
Most side effects present at 3 months (sensory changes, unsteadiness, gait disturbance) significantly reduce or resolve by 12 months as peri-lesional oedema settles
Permanent side effects: <5% — minimised at KIMS by step-by-step targeting with sub-therapeutic verification sonications before the therapeutic lesion is created
Partial tremor recurrence at 5 years: 10–20% — managed with repeat MRgFUS, DBS, or medication retrial
MRgFUS Results at a Glance
| Fact | Details |
|---|---|
| Primary evidence | NEJM 2016 RCT (Elias et al.): 47% vs 0% sham at 3 months · 75% at 12 months · 62% disability improvement · Double-blind, sham-controlled, 76 patients |
| 5-year durability | Halpern 2019: durable improvement in majority at 5 years · 10–20% partial tremor recurrence (not full return to baseline) · No new delayed side effects at 5 years |
| PD tremor evidence | Bond NEJM 2017: ~50% improvement vs sham · QOL improvement at 12 months · May have higher recurrence tendency as PD progresses |
| Side-effect table (key entries) | Sensory changes: 38% at 3 months → 14% at 12 months · Unsteadiness: 36% → 15% · Gait disturbance: 19% → 9% · Dysarthria: 6% → 3% · Permanent side effects: 3–5% |
| The six consent numbers | 47% (vs 0% sham at 3m) · 75% (at 12m) · 62% (disability improvement) · 80–85% (meaningful improvement) · 10–20% (partial recurrence at 5y) · <5% (permanent side effects) |
| Honest framing | 10–20% partial recurrence = some gradual tremor return, still substantially above baseline · 3–5% permanent side effect (usually sensory or balance) · Most side effects at 3 months resolve by 12 months |
| Contact | 040-44885000 · Previous KIMS MRgFUS patient consultation available on request · neuroscience@kimshospitals.com |
Related Treatments
Explore related MRgFUS pages at KIMS Neuroscience:
Frequently Asked Questions
Are You Eligible? Is the Expected Result Worth Pursuing? Both Answerable in a Single Day at KIMS Hyderabad.
The evidence is there. The experience is there. The technology is there — and it is the first of its kind in Telangana and Andhra Pradesh. The question is whether you are eligible and whether the expected result is worth pursuing. Both questions are answerable in a single assessment day at KIMS. Call 040-44885000.
International enquiries: info@kimsneurosciences.com